恩替卡韦联合多烯磷脂酰胆碱治疗乙型肝炎肝硬化疗效初步研究

doi:10.3969/j.issn.1672-5069.2017.05.034

Abstract

Xu Jian.. Combination of entecavir and polyene phosphatidyl choline therapy in treatment of patients with hepatitis B liver cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(5): 620-622.

[1] Wong GLH，Chan HLY，Mak CWH，et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology，2013，58（5）:1537-1547.
[2] Federico A，Dallio M，Di Fabio G，et al. Silybin-phosphatidylcholine complex protects human gastric and liver cells from oxidative stress. In Vivo，2015，29（5）:569-575.
[3] Clarke J D，Novak P，Lake AD，et al. Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease. Dig Dis Sci，2014，59（2）: 365-374.
[4] Kempen HJ，Asztalos BF，Moerland M，et al. High-density lipoprotein subfractions and cholesterol efflux capacities after infusion of MDCO-216（apolipoprotein a-imilano/ palmitoyl-oleoyl-phosphatidylcholine） in healthy volunteers and stable coronary artery disease patients. Arterioscl Thromb Vascul Biol，2016，36（4）:736-742.
[5] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2015年版）.实用肝脏病杂志，2016，19（3）：Ⅴ-ⅩⅩⅢ.
[6] Lok ASF，McMahon BJ，Brown RS，et al. Antiviral therapy for chronic hepatitis B viral infection in adults:a systematic review and meta-analysis. Hepatology，2016，63（1）:284-306.
[7] 张影，童霞，许晓梅. 血清Hs-CRP联合肝硬度检查在老年肝硬化合并肝癌患者中的诊断价值. 实用老年医学，2016，30（6）：472-474.
[8] Gil MN，Choi DR，Yu KS，et al. Rhus verniciflua stokes attenuates cholestatic liver cirrhosis-induced interstitial fibrosis via Smad3 down-regulation and Smad7 up-regulation. Anat Cell Biol，2016，49（3）:189-198.
[9] Brouwer WP，Xie Q，Sonneveld MJ，et al. Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B:a multicenter randomized trial（ARES study）. Hepatology，2015，61（5）:1512-1522.
[10] Papatheodoridis GV，Chan HLY，Hansen BE，et al. Risk of hepatocellular carcinoma in chronic hepatitis B:assessment and modification with current antiviral therapy. J Hepatol，2015，62（4）:956-967.
[11] 祝娟娟，吴娴，朱霞，等. 聚乙二醇干扰素联合恩替卡韦治疗15例慢乙肝的疗效观察. 贵州医药，2016，40（1）：76-77.
[12] 谢晖，刘红艳. 多烯磷脂酰胆碱、熊去氧胆酸、腺苷蛋氨酸对ICP患者的疗效及对ALT、AST等指标水平的影响. 海南医学院学报，2015，21（12）：1668-1670.
[13] 王丽. 甘草酸二铵、多烯磷脂酰胆碱对抗结核药物所致肝损伤的保护作用比较. 海南医学院学报，2016，22（20）：2490-2493.
[14] 肖丽萍，余新沛，刘岗，等. 多烯磷脂酰胆碱联合维生素E治疗非酒精性脂肪性肝炎合并2型糖尿病患者效果研究. 实用肝脏病杂志，2016，19（2）：172-175.
[15] Tang WHW，Wang Z，Shrestha K，et al. Intestinal microbiota-dependent phosphatidylcholine metabolites，diastolic dysfunction，and adverse clinical outcomes in chronic systolic heart failure. J Cardiac Fail，2015，21（2）:91-96.
[16] 周渝阳，皮儒先，陈平. 多烯磷脂酰胆碱对乙型病毒性肝炎致失代偿期肝硬化92例临床疗效观察. 海南医学院学报，2010，16（5）：577-578.
[17] 王美清，毛山山，程小珍，等. 多烯磷脂酰胆碱与异甘草酸镁预防化疗后肝功能异常的疗效比较. 中国现代医学杂志，2013，23（35）：103-106.
[18] 李继业，王薇，潘润华，等. 肝脏FibroScan测定和功能评分与肝硬化病理分级的相关性. 山东大学学报医学版，2014，52（12）：83-88.
[19] 周文策，王芳红，李营. 肝纤维化诊疗方法的研究进展. 中国普通外科杂志，2015，24（7）：1032-1037.
[20] Aubé C. Imaging modalities for the diagnosis of hepatic fibrosis and cirrhosis. Clin Res Hepatol Gastroenterol，2015，39（1）: 38-44.
[21] Shiha G，Seif S，Maher M，et al. Comparison between transient elastography（fibroscan） and liver biopsy for the diagnosis of hepatic fibrosis in chronic hepatitis C genotype 4. Egypt Liver J，2014，4（4）:106-111.
[22] Yada N，Kudo M，Kawada N，et al. Noninvasive diagnosis of liver fibrosis: utility of data mining of both ultrasound elastography and serological findings to construct a decision tree. Oncology，2014，87（s1）:63-72.
[23] Ning Q，Han M，Sun Y，et al. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B:a randomised open-label trial （OSST trial）. J Hepatol，2014，61（4）:777-784.

Combination of entecavir and polyene phosphatidyl choline therapy in treatment of patients with hepatitis B liver cirrhosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Bao Yingjun, Ren Weixin.. Interventional therapy for patients with portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 768-769.
[3]	National Workshop on Fatty Liver, Alcoholic Liver Disease, Chinese Society of Hepatology; National Workshop on Liver, Metabolism, Chinese Society of Endocrinology, Chinese Medical Association. Committee of Hepatology, Chinese Research Hospital Association; Fatty Liver Expert Committee, Chinese Medical Doctor Association [J]. Journal of Practical Hepatology, 2019, 22(6): 787-792.
[4]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[5]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[6]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[7]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[8]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[9]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[10]	Xing Xin, Wei Zhongcao, Zhou mimi, et al.. Efficacy and safety of tauroursodeoxycholic acid and ursodeoxycholic acid combination in the treatment of patients with nonalcoholic fatty liver disease:a Meta-analysis [J]. Journal of Practical Hepatology, 2019, 22(6): 852-855.
[11]	Duan Chuyao, Chen Qingshan, Wang Liming, et al.. Clinical efficacy of ursodeoxycholic acid in treatment of patients with intrahepatic cholestasis of pregnancy [J]. Journal of Practical Hepatology, 2019, 22(6): 864-867.
[12]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[13]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[14]	Chen Meimei, Duan Xiaoyan, Cao Haixia, et al.. Improvement of clinical symptoms and serum hepatic fibrosis markers in patients with primary biliary cirrhosis by compound Biejiaruangan tablets [J]. Journal of Practical Hepatology, 2019, 22(6): 880-883.
[15]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.